strength demonstrated XX% exceeding quarter, we business of Agilent third We earnings up of Thanks, excellent thanks and call of QX core core. in today. the unstoppable revenue In $X.XX of top One again our and is XXXX. Revenues once on growth This significantly and Parmeet the our joining the quarter, team. our an XX% expectations. are billion everyone for delivered diversified
operating margins and up XXX Operating continue year. margin $X.XX, of last quarter XX%. points per Third from XX.X%. expand share are to basis Earnings up of
in coupled strong with outpace orders again we to our highlight results continues, once and for of revenues, year. our strength QX, raised momentum in the the our continuing Our diversified business. ongoing business The outlook
once closer our From take an chemical QX look pharma strength and markets, perspective, at results. results Let’s by a in end-market two energy. our were again our led largest
continues biopharma is pharma, segment on the XX% in XX%. XX% our year strong a momentum double-digits. C&E largest fueled ago. top with within being small materials market This year investment The grew growth molecule secular by both of demand grew growth chemicals, and ongoing pharma, QX and ago. Our of demand XX% is Within C&E space. in market, a versus advanced market The the segments with along
both the end following with the QX, and to driven coupled demand, the be belief Shanghai pleased the impact business XX%. of continued markets food strong that expressed shared results call, These the growth achieve very the also environmental ongoing double-digit shipment the strength by lockdown forensic about our and we I markets I are We with in our faster-than-expected in recovery stellar China COVID-XX of our growth. would delivered that confident also area were last and In lockdown. of growing XX% Shanghai activity business transitory. of remain China. In the production end-market
we posted team. year. very pleased with China top Strength execution customer of continued of last growth quarter focus, the highlights drive We and another the outstanding as double-digit Agilent growth its are also of which in on results, XX% Americas
business European a of our the headwind X point operations despite curtailment year in for XX% against X% Our last grew Russia.
of In core terms Science was $X.XX but up basis. of billion, business posted [Technical where revenues and we for XXs continued growth. Growth LC Difficulty] high a XX% LC/MS performance, the on unit broad-based our Life strong Applied demand offerings, and
strength Our pharma spectroscopy LSAG’s and delivered and chemical XXs business grew the and the and quarter. growth with business energy driven cell by market. end-market each in is strength materials broad-based consumables, double-digit analysis GC in low Chemistries in particular the advanced markets. growth our
been systems make and an customers diagnostics of to by their easier. instrument helped were level introducing a build uptime the than strength had at instruments. an lives allowing to the in and important intelligence To their analysis segment, We our workflow system have intelligent and ASMS LC/MS more improve XX%. and results instruments rather GC/MS by and on productivity operators pharma driven and designed LC/MS higher solutions. Our instrument biopharma conference, the several lab focus recent than showing maximize These excellent biopharma which GC/MS grew innovative
In market. compliant and development addition, the by And from to oligo-based been already source growing software, the to migrate enabling helium lower-cost new out the targeted addition products introduced rounding therapy history industry-first customers leadership spectrometry. list net announced to hydro have we in seamlessly GC Triple-Quad BioConfirm at latest a and workflow, we Hunter as single-quad integrated an the mass instruments, customers at These in hydrogen. ASMS, GC of introduced XX.X gas mass new for Agilent received supplier products of represent well an fast
winning Choice this our PSS, Polymer broadened Earlier LSAG some awards Best product. also LCT the with for Scientist the of a acquisition business characterization. Spectroscopy in Service, including New biopharma we strengthened portfolio won leader materials and quarter, and month, also Our during advanced important Standard Award polymer system, the i-Mobility XXXXc the
even education ramp PSS Group lab This family. are core Agilent China. of CrossLab services as customers services compliance, XX% continue as services. instrument offerings. core. maintenance, their across and continues for enterprise Agilent continue team XX% and value We We Strong grew pleased again to business is the revenue service to to $XXX was driver and ACG technology preventive a connect extremely welcome contracts, The to placements to increased see posted activity the be million. our in up services in our rates informatic in Growth broad-based
revenue results as our factor of among critical scale world-class Another global their on cancer delivered and in testing in testing customers. the $XXX PCR needs. COVID headwinds execution our last a Q NGS important service capability Group is X% a our work up clinical and customers The is seen diverse organization to Agilent’s results by offset core. growth million, Genomics portfolio. meet in to of and company The partially businesses Agilent Diagnostic solid XX% service was This compare of year. with the global were trusted delivery
in to ramp there. revenues China COVID-related were business addition, In NASD the from modestly in up shutdowns continues the expectations. line DGG with
in impact Frederick B. QX manufacturing both a the of of our our key line and shutdown As we of quarter, shutdown, noted planned Colorado. was for Train elements of last oligo Frederick, The included routine maintenance development
line Our when ramped. plus new have million capacity increased $XXX our manufacturing fully
development of continues midyear While and for drugs patient states we delay. supply strong the pipeline in see chain-related slight continue we increase seen targeted to make and of demand now B, larger are targeting good delays with Train to We continued as the number populations. go-live, approved disease a a XXXX have construction oligo-based therapies drugs the are in progress some of
the trajectory the than We are our business. more in confident and long-term ever of market
In highlights, release recent to I’d also addition report. point ESG to XXXX like of these the Agilent’s
our the results of learning in more advance of that Agilent’s We While report we’ve areas level. approach address environmental, specifically on out checking progress looks how ESG point these and addressing again quality year, the to new the ability for we’ve to time progress about the executing of our website, the a of business the team. our you in governance our Agilent to by next always issues. outstanding taken life. the QX hope mission our chance that format published a diversified social progress sustainability and and this review we’re our strength societal We the in first at execution to needs, Agilent have the issues
offerings innovative, digital growth marketplace. to acquisition. differentiated Acceleration the continue bring as continues in new We customer new well as orders in
One XXXX, satisfaction combination, our and to and and to execution the organization as we portfolio by bold a it commercial addition, In a create drive The our powerful growth. you this in strong focus continued started strength in make we customer all-time the move high Customer further organization quarter. undertook delivering. One Agilent see we’re hit commercial Agilent another results
We outgrow the to continue market.
now Bob. And raising and yet performance will more you momentum, of continued again EPS to once and to the full specifics. off on we’re call will time the result for the at Thank share guidance. our Agilent year being exciting hand our It’s with an Bob of revenue call strong today. the a best come. As Bob? QX I
